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Abstract. A novel (S,S)-R2eddip ester, O,O′-diisopentyl-(S,S)-ethylenediamine- 
-N,N′-di-2-propanoate dihydrochloride (1) was synthesized and characterized 
by IR, 1H- and 13C-NMR spectroscopy, mass spectroscopy and elemental 
analysis. In vitro antitumor action of 1, and two more R2eddip esters, dialkyl 
(S,S)-ethylenediamine-N,N′-di-2-propanoate dihydrochlorides, obtained before 
(alkyl = n-Bu or n-Pe, 2 and 3, respectively), was determined against cervix 
adenocarcinoma (HeLa), human melanoma (Fem-x), human chronic 
myelogenous leukemia (K562) cells, and a non-cancerous cell line human emb-
ryonic lung fibroblast (MRC-5), using the microculture tetrazolium test MTT 
assay. Esters 1–3 showed higher cytotoxicity and better selectivity in com-
parison to cisplatin, used as reference compound. The highest activity was 
expressed by 1, with IC50(Fem-x) value of 1.51±0.09 µM.  
Keywords: R2edda-type esters; characterization; cytotoxicity; selectivity. 
INTRODUCTION 
Cancer is one of the most widespread and feared diseases in the world 
because it is very difficult to cure as cancer cells are not foreign to the body but 
are simply subtly mutated forms of normal human cells that multiply without 
control.1−3 
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The majority of drugs used for the treatment of cancer today are cytotoxic 
(cell-killing) drugs that work by interfering in some way with the operation of the 
cell’s DNA. 
Over the last fifty years, about 500,000 natural and synthetic chemical com-
pounds have been tested for their anticancer activity, but only about 25 of these 
are in wide use today.4 A major challenge is to design new drugs that will be 
more selective for cancer cells, and thus have fewer side effects. 
Cisplatin showed potent antitumor activity in the 70’s and nowadays it is 
routinely used in the treatment of many types of cancers.5−9 Unfortunately, it 
also causes severe side-effects, such as nephro-, oto- and neuro-toxicity.10,11 
Many platinum complexes were synthesized with hope for better pharmaco-
logical properties.12–14 Besides cisplatin, only carboplatin and oxaliplatin are in 
worldwide clinical use.15  
During the last decade, our research group has been engaged in the syn-
thesis, characterization and investigation of the antitumor activity of platinum(II) 
and platinum(IV) complexes with N,N′ bidentate ligands, R2edda-type esters.16−26 
These ligands, obtained by structural variations of the aminocarboxylato arms 
and alkyl groups of the ester moiety (normal, branched chains, rings), yielded a 
large library of such molecules (Fig. 1). In most cases, high cytotoxic action was 
accomplished when coordinating to platinum ions, but some of the esters, in fact, 
showed serious activity themselves.27,28 
 
Fig. 1. R2edda-type esters (* – esters investigated in this work). 
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These compounds (R2edda-type esters, R = alkyl; eddp = ethylenediamne-
N,N′-di-3-propanoate, Fig. 1, A; (S,S)-eddip = (S,S)-ethylenediamne-N,N′-di-2- 
-propanoate, Fig. 1, B; (S,S)-eddl = (S,S)-N,N′-1,2-ethanediylbisleucinate, Fig. 1, 
C; (S,S)-eddch = (S,S)-α,α′-(1,2-ethanediyldiimino)biscyclohexanepropanoate, 
Fig. 1, D) were tested against various cancer lines and normal cells and moderate 
or low activity was found,20,21,23,24,29,30 except for (S,S)-Et2eddch that had the 
lowest IC50 values ca. 11 µM against HL-60, U251, C6, L929 and B16 cell 
lines.27,28 
Herein, the synthesis, characterization and antiproliferative activity of one 
novel R2edda-type ester: diisopentyl (S,S)-ethylenediamine-N,N′-di-2-propanoate 
dihydrochloride (1) is reported. This newly synthesized compound, along with 
already reported22 di(n-butyl) (S,S)-ethylenediamine-N,N′-di-2-propanoate 
dihydrochloride (2) and di(n-pentyl) (S,S)-ethylenediamine-N,N′-di-2-propanoate 
dihydrochloride (3), were tested against cervix adenocarcinoma cell line (HeLa), 
human melanoma (Fem-x), human chronic myelogenous leukemia (K562) cells, 
and a non-cancerous cells MRC-5 (human embryonic lung fibroblast), with the 
aim of assessing their cytotoxic actions. 
EXPERIMENTAL 
Material and methods 
All reagents were of analytical grade. (S,S)-Ethylenediamine-N,N′-di-2-propanoic acid 
hydrochloride, (S,S)-H2eddip·HCl, was prepared by a standard procedure.31 
Elemental analyses were realized on an Elemental Vario EL III microanalyzer. The infra-
red spectra were recorded using a Nicolet 6700 FT-IR spectrophotometer (Thermo Scientific), 
ATR technique (smart accessory orbit with diamond crystal) in the range of 4000–400 cm-1. 
The NMR spectra were recorded on Varian Gemini 200 and Bruker Avance III 500 spec-
trometers. The chemical shifts for the 1H- and 13C-NMR spectra were referenced to residual 
1H and 13C present in DMSO-d6. The mass spectra were recorded with a 6210 Time-of-Flight 
LC–MS instrument (G1969A, Agilent Technologies). An Agilent Technologies 1200 series 
HPLC instrument (Agilent Technologies, Waldbronn, Germany) equipped with auto sampler, 
binary pump, DAD detector and ZDV cell, was used for the introduction of the sample 
dissolved in methanol into the mass spectrometer. As the mobile phase 0.2 % formic acid in 
water/acetonitrile (V/V = 50/50) at a flow of 0.15 mL min-1 was used. The mass spectra were 
recorded in the positive mode under the following conditions: capillary voltage 2500 V, gas 
temperature 250 °C, drying gas flow 7 L min-1, nebulizer pressure 30 psig, fragmentor voltage 
50 V, mass range 100–1500 m/z. For data collection and interpretation, MassHunter Work-
station software was used. 
An automatic polarimeter AUTOPOL® IV, Rudolph Research Analytical, a sodium lamp 
(589 nm) with a 1-dm cell was used to determine the specific rotation. 
Synthesis of (S,S)-(i-Pe)2eddip 2HCl (1)  
The R2edda-type ester, 1, was prepared using the esterification reaction previously 
described for similar compounds.18,32 Thionyl chloride (4 ml, 55 mmol) was introduced into a 
flask containing 40 ml of ice-cooled isopentyl alcohol (3-methyl-1-butanol), (t = 0 °C, anhyd-
rous conditions) during 1 h through a dropping funnel. Subsequently, 1.50 g (5.41 mmol) of 
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(S,S)-ethylenediamine-N,N′-di-2-propanoic acid hydrochloride, (S,S)-H2eddp·HCl, was added 
to the flask and the suspension was refluxed for 16 h at ≈130 °C. The mixture was filtered hot, 
immediately after reflux and the filtrate was left for a few days at 4 °C yielding the white 
product. 
Yield: 1.22 g, 54 %. Anal. Calcd. for C18H38N2O4Cl2·0.75H2O: C, 50.17; H, 9.23; N, 
6.50 %. Found: C, 50.07; H, 8.77; N, 6.44 %; IR (cm-1): 2961, 2862, 2636, 2598, 2416, 1733, 
1236, 1160, 803; 1H-NMR (500 MHz, DMSO-d6, δ / ppm): 0.90 (12H, d, 3JH,H = 6.5 Hz, 
CH3−i-Pe), 1.48–1.55 (10H, m, CH2−i-Pe, CH3), 1.68 (2H, sep, 3JH,H = 6.5 Hz, CH−i-Pe), 
3.31–3.47 (4H, m, CH2-(en)), 4.03 (2H, q, 3JH,H = 4.0 Hz, CH), 4.16–4.28 (4H, m, CH2O−i-
Pe), 10.09 (4H, brs, NH2+); 13C-NMR (50 MHz, DMSO-d6, δ / pm): 14.4 (CH3), 22.4 (CH3−i-
Pe), 24.5 (CH−i-Pe), 36.7 (CH2−i-Pe), 54.5 (CH2-(en)) 64.6 (CH), 70.2 (CH2O−i-Pe), 169.4 
(COO−i-Pe); ESI−MS (CH3OH), positive mode: Calcd. 345.27478. Found m/z: 345.27449 
[M–2Cl–H]+; 20D[ ]α = –15° (CH3OH, 1.1 mg/mL). 
Biological experiments 
Cell lines. Cervix adenocarcinoma cell line (HeLa), human melanoma (Fem-x), human 
chronic myelogenous leukemia (K562) cells, and a non-cancerous cell line, MRC-5 (human 
embryonic lung fibroblast) were grown in RPMI-1640 medium (Sigma Aldrich, St. Louis, 
MO, USA). The media were supplemented with 10 % fetal bovine serum, L-glutamine, and 
penicillin–streptomycin (Sigma Aldrich, St. Louis, MO, USA). 
Treatment of cell lines. The target cells HeLa (2000 cells per well), Fem-x (5000 cells 
per well), K562 (5000 cells per well), and non-cancerous MRC-5 (5000 cells per well) were 
seeded into wells of a 96-well flat-bottomed microtitre plate. Twenty-four hours later, after 
cell adherence, different concentrations of the investigated compounds were added to the 
wells, except for the control cells to which the nutrient medium only was added. The final 
chosen concentrations range was 1–100 µM (1.0, 8.25, 16.5, 33.0 and 100.0 µM). The final 
concentration of DMSO solvent never exceeded 0.5 %, which was non-toxic to the cells. 
Especially, compounds were applied to the suspension of K562 cells 2 h after cell seeding. All 
concentrations were set up in triplicate. Nutrient medium with corresponding concentrations 
of investigated compounds, but without cells, was used as a blank, also in triplicate. The cul-
tures were incubated for 72 h. 
Determination of cell survival. The effect of the prepared compounds on cancer cell 
survival was determined by the microculture tetrazolium test (MTT) according to Mosmann33 
with modification by Ohno and Abe34 72 h after addition of the compounds, as described 
earlier. Briefly, 20 µl of methylthiazoletetrazolium bromide, 2-(4,5-dimethyl-2-thiazolyl)-3,5-
diphenyl-2H-tetrazolium bromide (MTT) solution (5 mg ml-1 phosphate-buffered saline) was 
added to each well. Samples were incubated for a further 4 h at 37 °C in a humidified 
atmosphere of 95 vol. % air/5 vol. % CO2. Then 100 µL of 100 g L-1 sodium dodecyl sulfate 
solution was added to extract the insoluble product formazan resulting from the conversion of 
the MTT dye by viable cells. The number of viable cells in each well was proportional to the 
intensity of the absorbance of light, which was read in an enzyme-linked immunosorbent 
assay (ELISA) plate reader at 570 nm. The absorbance (A) at 570 nm was measured 24 h later. 
To determine cell survival (%), the A of a sample with cells grown in the presence of various 
concentrations of the investigated compounds was divided by the control optical density (the 
A of control cells grown only in nutrient medium) and multiplied by 100. Absorbance of the 
blank was always subtracted from the A of the corresponding sample with target cells. The 
IC50 is defined as the concentration of an agent inhibiting cell survival by 50 % compared 
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with an untreated control. Cisplatin was used as the positive control. All experiments were 
performed in triplicate. 
The selectivity index. The selectivity index (SI) is defined as the ratio of the IC50 obtained 
from the experiments on normal cells to that obtained on cancer cells. As the selectivity index 
(SI) demonstrates the differential activity of a pure compound, the greater the SI value is, the 
more selective is the compound.35,36 
Statistical analysis 
Results are presented as the mean ± standard deviation (SD) of triplicate observations 
from the representative of three experiments. The significance of the difference between 
treatments and control was analyzed by ANOVA followed by the Student-Newman-Keuls test 
P < 0.05 was considered significant.  
RESULTS AND DISCUSSION 
Spectroscopic studies 
In the reaction of (S,S)-ethylenediamine-N,N′-di-2-propanoic acid hydro-
chloride, (S,S)-H2eddip·HCl (crystal structure was described recently),37 with 
absolute isopentyl alcohol (3-methyl-1-butanol) in the presence of thionyl chlo-
ride, diisopentyl (S,S)-ethylenediamine-N,N′-di-2-propanoate dihydrochloride (1) 
was obtained (Scheme 1). 
 
Scheme 1. Synthesis of (S,S)-(i-Pe)2eddip·2HCl (1). 
The IR spectrum of 1 showed characteristic absorption bands for this class of 
compounds.22,23,28 A strong absorption stretching band ν(C=O) was found at 
1733 cm−1, while a band arising from ν(C−O) appeared at 1236 cm−1. Asym-
metric CH3 stretching vibrations of medium intensity were found at ν(CH3) 2961 
cm−1 and 2862 cm−1. Furthermore, an asymmetric ν(C−N) stretching vibration 
was found at 803 cm−1. 
In the 1H-NMR spectrum resonances of methyl hydrogen atoms from the 
isopentyl moieties were found at 0.90 ppm as a doublet. Chemical shifts of the 
hydrogen atoms from isopentyl-CH2 groups, overlapped with CH3 protons 
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(L-alanine moiety), were found as a multiplet at 1.48–1.55 ppm, while CH2 
protons belonging to carbon atoms attached to ester oxygen could be seen at 4.21 
ppm. Hydrogen atoms belonging to tertiary carbon atoms (isopentyl groups) were 
found as a septet at 1.69 ppm. The CH protons from the L-alanine moiety were 
detected at 4.03 ppm. The chemical shifts assignable to −N−CH2−CH2−N− pro-
tons were found at 3.31–3.47 ppm. Resonances of hydrogen atoms belonging to 
secondary ammonium groups were found at 10.09 ppm as broad singlets. 
In the 13C-NMR spectrum, the carbonyl carbon atoms peak was found at 
169.4 ppm as expected for this class of compounds.23,29 The ethylenediamine 
carbon atoms resonated at 54.5 ppm. The carbon atoms bonded to the ester oxy-
gens were detected at 70.2, but resonances of all other carbon atoms (from iso-
pentyl and L-alanine moieties) were found below 40 ppm, as expected.22 The 
high resolution mass spectrum (positive mode) of 1 showed the presence of 
[M–2Cl–H]+.  
In vitro studies 
Cytotoxicity. The in vitro cytotoxicity of esters 1–3 toward HeLa cervix 
adenocarcinoma, Fem-x human melanoma, K562 human chronic myelogenous 
leukemia cell lines and non-cancerous MRC-5 human embryonic lung fibroblast 
cells were determined by MTT assay. Cisplatin was used as a reference. The 
results are summarized in Table I, while Fig. 2 depicts the cytotoxic curves from 
the MTT assay showing the survival of target cells grown for 72 h in the pre-
sence of increasing concentrations of 1–3. 
TABLE I. IC50 values (µM) for 1–3 and cisplatin on the malignant HeLa, Fem-x and K562 
cell lines and non-cancerous MRC-5 normal cells; the IC50 values are expressed as the mean±SD 
determined from the results of the MTT assay in three independent experiments 
Compound Cell line 
HeLa Fem-x K562 MRC-5 
1 2.01±0.19 1.51±0.09 5.22±0.55 51.09±1.06 
2 2.22±0.81 2.25±0.91 3.27±0.58 >100 
3 1.75±0.44 2.31±0.79 2.13±1.45 53.79±0.84 
Cisplatin 2.10±0.20 5.51±0.31 5.54±1.03 14.21±1.54 
The investigated compounds demonstrated a remarkable cytotoxic activity, 
as the IC50 values are in range from 1.51 to 5.22 µM against all the tested malig-
nant cell lines. The IC50 values of these compounds against all cancer cell lines 
were in the micromolar range, similar to or better than those of the antitumor 
drug cisplatin. Namely, 1–3 and cisplatin showed no significant difference in in 
vitro activity against HeLa cells. Furthermore, all compounds exhibited signi-
ficantly higher activity than cisplatin against K562 and Fem-x cell lines, except 
complex 1 against K562 cells. 
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Fig. 2. Representative graphs show the survival of HeLa, K562, Fem-x, and MRC-5 cells 
grown for 72 h in the presence of increasing concentrations of 1–3. 
These findings indicate that the described compounds are extremely impor-
tant for the future screening of their biological activity. In addition, from the 
obtained results, it could be concluded that compounds 1–3 show very slight 
differences in their cytotoxic effects against the tested cancer cells. Obviously, 
the presence of the isopentyl, n-butyl or n-pentyl groups in the structure of these 
compounds does not lead to significant differences in their activities.  
Selectivity. Against the non-cancerous lung fibroblasts (MRC-5), all of the 
compounds exhibited a significantly weaker activity compared to cisplatin. The 
toxicity of compounds 1 and 3 in the lung fibroblasts was almost four times 
lower than that of cisplatin (Table I), and ten to fifty times weaker in the healthy 
cells compared to all the tested cancerous cells (Table II). Remarkably, compound 
2 showed no cytotoxicity to normal non-cancerogenic MRC-5 cells (IC50 > 100 
µM). The present in vitro experiments showed that compounds 1–3 express very 
high cytotoxic activity to cancerous cells with great selectivity (Table II), 
whereby compound 2 had no cytotoxic activity against mammalian normal cells 
(in the investigated concentration range). The effects of these compounds 
towards cancer and normal cells indicate to the necessity for further studies with 
in vitro and/or in vivo tests. 
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TABLE II. Selectivity index (SI =IC50(MRC-5)/IC50(cell line)) 
Compound Cell 
HeLa Fem-x K562 
1 25.42±0.19 33.83±2.14 9.79±1.05 
2 > 45.05 > 44.44 > 30.58 
3 30.74±7.74 23.29±7.97 25.25±17.20 
Cisplatin 6.77±0.98 2.58±0.31 2.56±0.55 
CONCLUSIONS 
The R2eddip ester, diisopentyl (S,S)-ethylenediamine-N,N′-di-2-propanoate 
dihydrochloride (1) was synthesized. The compound was characterized by IR, 
1H- and 13C-NMR spectroscopy, mass spectrometry and by elemental analysis. 
This novel R2eddip⋅2HCl, 1, ester along with earlier reported di(n-butyl) (S,S)-
ethylenediamine-N,N′-di-2-propanoate dihydrochloride (2) and di(n-pentyl) 
(S,S)-ethylenediamine-N,N′-di-2-propanoate dihydrochloride (3) were tested 
against cervix adenocarcinoma cell line (HeLa), human melanoma (Fem-x), 
human chronic myelogenous leukemia (K562) cells and the non-cancerous cell 
line human embryonic lung fibroblast (MRC-5), using the MTT assay. Esters 1–3 
showed similar or higher cytotoxicity, but much better selectivity, in comparison 
to cisplatin. (S,S)-(i-Pe)2eddip (1) expressed the highest activity against Fem-x 
cells (IC50 = 1.51±0.09 µM). 
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И З В О Д  
СИНТЕЗА И ВИСОКА IN VITRO ЦИТОТОКСИЧНОСТ НЕКИХ (S,S)-ЕТИЛЕНДИАМИН- 
-N,N′-ДИ-2-ПРОПАНОАТ-ДИХИДРОХЛОРИД ЕСТАРА 
НЕБОЈША ПАНТЕЛИЋ1, БОЈАНА Б. ЗМЕЈКОВСКИ2, ТАТЈАНА П. СТАНОЈКОВИЋ3, ВЕРИЦА В. ЈЕВТИЋ4, 
ГОРДАНА П. РАДИЋ4, СРЕЋКО Р. ТРИФУНОВИЋ4, ГОРАН Н. КАЛУЂЕРОВИЋ5 и ТИБОР Ј. САБО6 
1Пољопривредни факултет, Универзитет у Београду, Немањина 6, 11080 Београд-Земун, 2Центар за 
хемију – Институт за хемију, технологију и металургију, Универзитет у Београду, Његошева 12, 
11000 Београд, 3Инстритут за онкологију и радиологију, 11000 Београд, 4Институт за хемију, 
Природно–математички факултет, Универзитет у Крагујевцу, Р. Домановића 12, 34000 Крагујевац, 
5Department of Bioorganic Chemistry, Leibniz Institute of Plant Biochemistry, Weinberg 3, D-06120 Halle 
(Saale), Germany и 6Хемијски факултет, Универзитет у Београду, n.np. 158, 11001 Београд 
Нов (S,S)-R2eddip естар, О,О′-диизoпентил-(S,S)-етилендиамин-N,N′-ди-2-пропа-ноат-дихидрохлорид (1), синтетисан је и окарактерисан уз помоћ IR, NMR и масене 
спектрометрије и елементалне анализе. In vitro антитуморска активност једињења 1, и 
још два R2eddip естра, О,О′-диалкил-(S,S)-етилендиамин-N,N′-ди-2-пропаноат-дихидро-хлорида, који су раније објављени (алкил = n-Bu или n-Pe, 2 и 3, редом) испитивани су 
на хуманим ћелијским линијама аденокарцинома материце (HeLa), малигног меланома 
(Fem-x), и мијелоидне леукемије (K562), као и на нормалној ћелијској линији MRC-5 
(фетални плућни фибробласти), уз помоћ МТТ теста. Естри 1−3 су показали високу 
цитотоксичност и бољу селективност у поређењу са цисплатином којa је коришћенa као 
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референтна супстанца. Највећу активност је показао естар 1 са IC50(Fem-x) вредношћу 
1,51±0,09 μM. 
(Примљено 5. децембра 2013, ревидирано 13. марта, прихваћено 17. марта 2014) 
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